1.Green MR. Targeting targeted therapy. N Engl J Med. 2004 May 20;350(21):2191-3. Epub 2004 Apr 29.
2.Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39.
3.Nyati MK, et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006;6(11):876-85.
4.Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med. 2004 May 20;350(21):2129-39.
5.Liu X et al. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget. 2017 Jul 25;8(30):50209-50220.
6.Thatcher N, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37.
7.Fukuoka M, et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
8.Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57.
9.Maemondo M et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8.
10.Mitsudomi T et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010 Feb;11(2):121-8.
11.Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib assecond-line treatment of patients with advanced squamous cell carcinoma of thelung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015;16:897-907.
12.Mok TS,Wu YL, Ahn M-J,et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J].N Engl J Med,2017;376(7):629-640.
14.Han B， Li K， Wang Q， et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerThe ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online August 09， 2018. doi:10.1001/jamaoncol.2018.3039.
15.Han B, Li K, Wang Q, et al. Efficiency of anlotinib as 3rdline treatment in patients with different EGFR gene status, an exploratorysubgroup analysis of ALTER0303 trial[J]. Journal of Thoracic Oncology, 2017,12(11).